Cite
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: Correlation with MGMT promoter methylation status
MLA
Antonella Bacci, et al. Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients with Glioblastoma: Correlation with MGMT Promoter Methylation Status. Jan. 2009. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e79a36071ed05729fafe551737d80122&authtype=sso&custid=ns315887.
APA
Antonella Bacci, Francesca Benevento, Alicia Tosoni, Alba A. Brandes, Valeria Mazzocchi, Fabio Calbucci, Mario Ermani, Raffaele Agati, L. Scopece, & Enrico Franceschi. (2009). Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: Correlation with MGMT promoter methylation status.
Chicago
Antonella Bacci, Francesca Benevento, Alicia Tosoni, Alba A. Brandes, Valeria Mazzocchi, Fabio Calbucci, Mario Ermani, Raffaele Agati, L. Scopece, and Enrico Franceschi. 2009. “Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients with Glioblastoma: Correlation with MGMT Promoter Methylation Status,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e79a36071ed05729fafe551737d80122&authtype=sso&custid=ns315887.